- Home
- INCY
INCY
Incyte Corp.
as 03-11-2025 4:00pm EST
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 13.4B | IPO Year: | 1993 |
| Target Price: | $74.38 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -94.34 |
| 52 Week Low/High: | $50.35 - $83.95 | Next Earning Date: | 04-29-2025 |
| Revenue: | $4,241,216,999 | Revenue Growth: | 14.76% |
| Revenue Growth (this year): | 12.23% | Revenue Growth (next year): | 8.89% |
Stock Insider Trading Activity of Incyte Corp. (INCY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Denton Sheila A. | INCY | EVP & General Counsel | Mar 4 '25 | Sell | $69.99 | 599 | $41,924.01 | 25,848 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Feb 26 '25 | Sell | $74.07 | 14,069 | $1,042,135.78 | 25,848 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Jan 17 '25 | Sell | $72.69 | 12,352 | $897,866.88 | 66,967 | |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 13 '24 | Sell | $69.98 | 1,300 | $90,967.50 | 23,962 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
Benzinga
16 hours ago
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Benzinga
a day ago
Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
Zacks
2 days ago
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
Zacks
2 days ago
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
MT Newswires
2 days ago
Eli Lilly, Incyte Report Significant Hair Regrowth in Adolescents Treated With Baricitinib
PR Newswire
3 days ago
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Business Wire
4 days ago
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
Business Wire
4 days ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare INCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.